10x Genomics
TXG
275 hedge funds and large institutions have $5.6B invested in 10x Genomics in 2023 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 98 increasing their positions, 80 reducing their positions, and 37 closing their positions.
222% more call options, than puts
Call options by funds: $22.7M | Put options by funds: $7.04M
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
65% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 37
49% more capital invested
Capital invested by funds: $3.75B → $5.6B (+$1.85B)
23% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 80
8.6% more ownership
Funds ownership: 87.55% → 96.15% (+8.6%)
7% more funds holding
Funds holding: 256 → 275 (+19)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$174M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$45.6M |
| 3 |
SW
SVB Wealth
Boston,
Massachusetts
|
+$30.2M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$24.6M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$24.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$37M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$18.3M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$17.2M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$15.9M |
| 5 |
SIM
SRS Investment Management
New York
|
-$15.9M |
TXG Hedge Fund Activity: Q4 2023 in Review
275 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q4 2023, worth a combined $5.6B — up 49% from $3.75B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new TXG positions and 37 closed out — a net gain of 24 holders — while 98 added to existing stakes and 80 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $174M. The largest seller was Point72 Asset Management, cutting an estimated $37M.
- 275 institutional investors held 10x Genomics (TXG) as of Q4 2023, up from 256 in Q3 2023.
- Funds reported $5.6B of 10x Genomics stock for Q4 2023, up 49% quarter-over-quarter.
- 61 funds opened new 10x Genomics positions in Q4 2023 and 37 closed out, a net change of +24 holders.
- The largest 10x Genomics buyer in Q4 2023 was Morgan Stanley, an estimated $174M added.
- The largest 10x Genomics seller in Q4 2023 was Point72 Asset Management, an estimated $37M sold.
Based on aggregated 13F filings for Q4 2023.